$106.82
2.342.24%
Last update: Nov 11, 4:00 PM
Spyre Therapeutics Inc
SYRENASDAQ
Spyre Therapeutics rose 357.5% from $23.35 to $106.82, ahead of the S&P 500's +11.2%. Its worst day was Oct 6 (−13.6%), and its low came Nov 13 at $22.63.
Nov 11, 2025 – Nov 11, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Spyre Therapeutics closed at its lowest level of the year, 3.1% below where the year started.
−3.4% · S&P 500 −1.7%
Spyre Therapeutics shares rose 11.2%, while the S&P 500 rose 1.5%.
+11.2% · S&P 500 +1.5%
Story events cover the past 12 months · Times ET
EPS of $-0.70 beat the $-0.74 estimate on $0.00 revenue (est. $111,110.00).
+14.3% · S&P 500 +0.7%
Following the announcement, the Company will host a conference call and webcast at 8:00am ET on Monday April 13, 2026 to discuss the results.
+23.4%, the year's best day, on 5M shares, the year's heaviest volume · S&P 500 +1.0%
EPS of $-0.74 missed the $-0.66 estimate on $0.00 revenue.
+2.7% · S&P 500 +0.8%
Spyre Therapeutics shares rose 13.6%, while the S&P 500 fell 0.3%.
+13.6% · S&P 500 −0.3%
EPS of $-0.36 beat the $-0.74 estimate on $0.00 revenue.
−0.6% · S&P 500 −0.2%
Spyre Therapeutics shares fell 12.8%, while the S&P 500 rose 0.0%.
−12.8% · S&P 500 0.0%
Spyre Therapeutics shares fell 13.6%, while the S&P 500 rose 0.5%.
−13.6%, the year's worst day · S&P 500 +0.5%
EPS of $-0.94 missed the $-0.83 estimate on $0.00 revenue.
−0.2% · S&P 500 +1.7%
Where it ended: a close of $106.82 on Nov 11, 2026. Up next: Q4 2026 earnings on Feb 18, 2027 (EPS est. $-0.96).
Nothing in the past 12 months.
All SYRE dividend historyReplay the year: the line draws itself and stops at each of the 10 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for SYRE and SPY from Benzinga historical bars. Not investment advice.
